Immunotherapy for Ovarian Cancer: Adjuvant, Combination, and Neoadjuvant.
Immunotherapy for Ovarian Cancer: Adjuvant, Combination, and Neoadjuvant.
复制标题
卵巢癌的免疫疗法：佐剂、联合疗法和新佐剂
DOI：
10.3389/fimmu.2020.577869
复制
发表时间：
2020
影响因子：
7.3
通讯作者：
Jin WL
中科院分区：
文献类型：
--
作者：
Yang C;Xia BR;Zhang ZC;Zhang YJ;Lou G;Jin WL
卵巢癌是最致命的妇科恶性肿瘤。手术和化疗是卵巢癌的主要治疗方法;然而，患者通常在初次治疗后几年内因化疗耐药而复发。在过去的二十年里，免疫疗法迅速发展，并彻底改变了各种类型癌症的治疗。尽管卵巢癌患者的免疫治疗反应率仍然适中，但免疫检查点抑制剂（ICI），嵌合抗原受体（CAR）和TCR工程化T细胞的治疗正在迅速发展。如果将免疫疗法作为辅助疗法，与化疗、放疗、抗血管生成药物和聚ADP核糖聚合酶抑制剂（PARPi）联合使用，则治疗效率可显著提高。新开发的识别治疗靶点、预测治疗效果、快速筛选潜在免疫治疗药物、提供新辅助免疫治疗、利用纳米医学技术等技术为卵巢癌的治疗提供了新的机遇，并有可能延长患者的生存期。然而，为了使这些疗法有效，必须考虑和解决可能阻碍这些方法的功效的重要问题，包括超进展性疾病（HPD）、免疫疗法抗性和治疗的毒性（包括神经毒性）。
Ovarian cancer is the most lethal gynecologic malignancy. Surgery and chemotherapy are the primary treatments for ovarian cancer; however, patients often succumb to recurrence with chemotherapeutic resistance within several years after the initial treatment. In the past two decades, immunotherapy has rapidly developed, and has revolutionized the treatment of various types of cancer. Despite the fact that immunotherapy response rates among ovarian cancer patients remain modest, treatment with immune checkpoint inhibitors (ICIs), chimeric antigen receptor (CAR)- and TCR-engineered T cells is rapidly developing. Therapeutic efficiency could be improved significantly if immunotherapy is included as an adjuvant therapy, in combination with chemotherapy, radiation therapy, and the use of anti-angiogenesis drugs, and poly ADP ribose polymerase inhibitors (PARPi). Newly developed technologies that identify therapeutic targets, predict treatment efficacy, rapidly screen potential immunotherapy drugs, provide neoadjuvant immunotherapy, and utilize nanomedicine technology provide new opportunities for the treatment of ovarian cancer, and have the potential to prolong patient survival. However, important issues that may hinder the efficacy of such approaches, including hyperprogressive disease (HPD), immunotherapy-resistance, and toxicity of the treatments, including neurotoxicity, must be taken into account and addressed for these therapies to be effective.
登录
查看更多内容
影响因子：
10.9
作者：
Bakos O;Lawson C;Rouleau S;Tai LH
通讯作者：
Tai LH
DOI：
10.1038/nri3921
发表时间：
2015-12
期刊：
Nature reviews. Immunology
影响因子：
--
作者：
通讯作者：
--
影响因子：
11.5
作者：
Chen, Yuhui;Sun, Chuang;Savoldo, Barbara
通讯作者：
Savoldo, Barbara
影响因子：
7.3
作者：
Baert, Thais;Vankerckhoven, Ann;Coosemans, An
通讯作者：
Coosemans, An
影响因子：
19
作者：
Dai, Liangliang;Li, Ke;Cai, Kaiyong
通讯作者：
Cai, Kaiyong